BRAF and melanoma: Given that some studies found promising clinical responses but a problem with toxicity with certain combinations [71], other trials are evaluating sequential treatment with targeted therapy and immunotherapy in patients with BRAF-mutant melanoma, in order to identify the optimal sequencing and timing of treatment [21,48].